Tag Archives: Ed Arce

Analysts’ Top Healthcare Picks: Durect (DRRX), Co-Diagnostics (CODX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Durect (DRRX – Research Report) and Co-Diagnostics (CODX – Research Report) with bullish sentiments. Durect (DRRX) H.C. Wainwright analyst Ed Arce maintained

Analysts Offer Insights on Healthcare Companies: CymaBay Therapeutics (NASDAQ: CBAY), Novan (NASDAQ: NOVN) and Turning Point Therapeutics (NASDAQ: TPTX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on CymaBay Therapeutics (CBAY – Research Report), Novan (NOVN – Research Report) and Turning Point Therapeutics (TPTX – Research Report) with bullish sentiments.

H.C. Wainwright Maintains a Buy Rating on Iterum Therapeutics (ITRM)

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Iterum Therapeutics (ITRM – Research Report) today and set a price target of $9.00. The company’s shares closed last Thursday at $3.50. According to TipRanks.com, Arce is a 5-star analyst

Avenue Therapeutics (ATXI) Gets a Buy Rating from H.C. Wainwright

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Avenue Therapeutics (ATXI – Research Report) today and set a price target of $13.00. The company’s shares closed last Tuesday at $10.20. According to TipRanks.com, Arce is a 5-star analyst

Durect (DRRX) Gets a Buy Rating from H.C. Wainwright

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Durect (DRRX – Research Report), with a price target of $5.50. The company’s shares closed last Tuesday at $2.55. According to TipRanks.com, Arce is a

H.C. Wainwright Maintains a Buy Rating on Dicerna Pharma (DRNA)

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Dicerna Pharma (DRNA – Research Report) today and set a price target of $32.00. The company’s shares closed last Thursday at $22.85. According to TipRanks.com, Arce is a 5-star analyst